Drug Quality Screening Technology Recognized - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Drug Quality Screening Technology Recognized


PharmaCheck, a portable tool designed to detect poor-quality medicines, has been selected by Scientific American as one of the magazine’s World Changing Ideas of 2013. The device was developed by researchers from Boston University (BU) in collaboration with the Promoting the Quality of Medicines (PQM) program of the US Pharmacopeial Convention (USP).

BU and USP scientists have spent the last two years honing the technology behind PharmaCheck into an inexpensive, portable tool capable of assessing active ingredients in medicines.

PharmaCheck uses a fluorescent probe tailored to bind to an active ingredient in a specific drug and a silicon-polymer testing chip that detects the amount of light the probe emits. Software translates that light reading into an estimate of active ingredient concentration. Monitoring that signal over time indicates the ingredient’s dissolution. Within minutes, a doctor, regulatory official or health worker can have critical insight about the quality of a medicine sample.

Since 2009, USP has been providing technical assistance to regulatory, quality control and health care personnel in developing countries via PQM as a central strategy in the fight against substandard and counterfeit medicines

In early 2014, BU researcher Muhammad Zaman, developer of the technology, will conduct field tests on PharmaCheck through USP’s Center for Pharmaceutical Advancement and Training (CePAT) in Accra, Ghana. The field tests will include probes for an antimalarial and an antibiotic drug.

 

Source: US Pharmacopeial Convention

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here